Background and Objectives: Bacterial resistance to antibiotics has motivated the researchers to evaluate the novel anti-bacterial compounds such as some thiazole and imidazole derivatives. Thereby, in this work, we investigated the anti-bacterial effects of one new thiazole and two new imidazole derivatives on Bacillus cereus, Listeria monocytogenes, Escherichia coli, Salmonella typhimurium, Proteus mirabilis and Shigella dysenteriae.
the developing countries. These agents usually spread quickly, and the most susceptibilities to them have been assigned to the immunocompromised persons, pregnant mothers, children, and older individuals (1) . Along with the progressive resistance of bacteria to the current antibiotics as a result of irregular antibiotic consumption in medicine, the health and general hygiene of people are strongly at risk, and, therefore, to avoid this threat, identification and utilizing novel anti-bacterial compounds are required (2) . In the recent years, experimental researches have introduced some thiazole derivatives as the multi-therapeutic 
INTRODUCTION
Pathogenic bacteria have caused serious diseases and a lot of mortality in many nations, especially in effect compounds including anti-cancer, anti-inflammatory, and inhibitor of the parasites like Leishmania and the fungi such as Candida (3) (4) (5) (6) . Moreover, the anti-bacterial effects of these compounds have been proven on a wide range of pathogens like Bacillus subtilis, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella aerogenes so that their potency and broad spectrum activity have promised the researchers to replace them with out-dated drugs to which the bacteria are resisting (7) . Also regarding the imidazole derivatives, many properties such as the anti-fungal, anti-viral, anti-parasitic, and in-vitro inhibition of cancer cells have been demonstrated, and studying the anti-bacterial effects of these compounds has emphasized their power to inhibit the bacteria such as Enterococcus faecalis, Staphylococcus aureus, and Pseudomonas aeruginosa (8) (9) (10) (11) . The potent and wide range anti-bacterial properties of the thiazole and imidazole derivatives have generally made the anti-bacterial test to be among the initial experiments that are studied after synthesizing these agents. In this study, we evaluated the in-vitro anti-bacterial effects of two novel imidazole and one new thiazole derivatives, which have recently been synthesized in Iran, against the bacterial pathogens that are often transferred to the human body by means of food, and cause disease.
MATERIALS AND METHODS
Synthesis of derivatives. The No. 6 thiazole derivative ( Fig. 1 ) was incorporated into a three-phase process, and its chemical structure was verified by monocrystal X-ray diffraction, 1H NMR, 13C NMR, and IR spectroscopic techniques, element decomposition technique, and spectrophotometry. This synthesized derivative was then dissolved in DMSO (8000 µg/mL) (12) .
The 3a-b imidazole derivatives were synthesized in a mono-phase process from malononitrile (10 mM, 1.7 g) and 2a-b diaminoalkanes (10 mM), and their chemical structures were confirmed by monocrystal X-ray diffraction, 1 HNMR, 13 CNMR, and IR spectroscopic techniques, element decomposition technique,and spectrophotometry. These compounds were then dissolved in DMSO (8000 µg/mL) (13). 8 CFU/mL) was obtained using a spectrophotometer and a standard McFarland tube number 0.5 from each bacterium, which was assigned as the stock solution (14) .
Minimum inhibitory concentration (MIC)
determination. The MIC test was carried out in a sterile 96-well plate by broth microdilution as the CLSI (15) standard. First, 90 µL of the Muller-Hinton broth medium (Merck ® , Germany) was added to each well. Then 100 µL of the thiazole and imidazole derivatives (in control groups, 100 µL of penicillin and gentamycin antibiotics (Sigma ® ) with the primary concentration of 256 µg/ml) were added to the first well (in which the concentration of derivatives was 4000 and concentration of antibiotics was 128 µg/ml). After mixing, 100 µL of this mixture was embedded into the second well. Similarly, the dilution procedure was carried out in the other wells. 10 µL of the bacterial suspension was added to each well. For a negative control, 100 µL of the Muller-Hinton broth, 100 µL of DMSO, and 10 µL of the bacterial suspension were added to the last well in each row. The incubation result was read after 24 h incubation at 37 o C. The lucidity and turbidity in each well indicated the lack and existence of the bacterial growth, respectively. The last well that did not show any turbidity by visual method was reported as MIC (14) .
Growth inhibition zone diameter determination. Firstly, in the Muller-Hinton agar medium, the superficial bacterial culture was performed with a swab impregnated to the bacterial suspension. Then 20 µL of the MIC imidazole and thiazole derivatives obtained and also the antibiotics were shed on blank sterile disks. For the negative control, the DMSO-impregnated disk was used. After 24 h incubation at 37 o C, the growth inhibition zone diameter was measured using a particular ruler. The results of the growth inhibition zone diameter were provided as the average ± standard deviation, and for the aim of analyzing the data, the SPSS statistical software (version 22) was used (14) .
RESULTS
In this study, the anti-bacterial effects of the 3a-b imidazole derivatives and compound 6 of thiazole were assessed for E. coli, S. dysenteriae, S. typhimurium, P. mirabilis, B. cereus, and L. monocytogenes by means of the growth inhibition zone diameter and MIC measurements. No inhibitory effect of the 3a-b imidazole derivatives against all of the tested bacteria was observed, and only compound 6 of thiazole had an inhibitory effect against S. dysenteriae, P. mirabilis, and L. monocytogenes, among the tested bacteria. The inhibitory effect of this compound was recorded with the MIC values of 1000, 125, and 1000 µg/ mL, and the zone diameter values of 9.3 ± 0.1, 15.6 ± 0.2, and 8.1 ± 0.0 mm for P. mirabilis, S. dysenteriae, and L. monocytogenes, respectively. In the anti-biogram test performed, the most and least susceptibilities were recorded for B. cereus to gentamicin with the MIC value of 0.5 µg/mL, and for E. coli to penicillinwith the MIC value of 64 µg/mL (Tables 1  and 2 ). Table 1 . MIC values (µg/mL) for effects of thiazole and imidazole derivatives and antibiotics on tested bacteria. There has been a focus on the anti-bacterial activities of the thiazole derivatives in many research works, in which the growth inhibition zone diameter or MIC or both have been measured. In this regard, we can refer to the research work carried out by Jagani et al. in which they have shown the in-vitro anti-bacterial potency of the thiazole derivatives against Bacillus subtilis, Bacillus megaterium, Escherichia coli, and Pseudomonas aeruginosa by measuring the growth inhibition zone diameter (23). Bharti et al. have
ANTIBACTERIAL EFFECTS OF THIAZOLE & IMIDAZOLE DERIVATIVES

DISCUSSION
Thiazole and imidazole derivatives with high potencies of anti-bacterial activity could be some novel compounds that are used as antibiotics, and in many countries, are in focus of research fields. According to the results obtained for this work, the 3a-b compounds (two imidazole derivatives) lacked any inhibitory effect on the tested bacteria, whereas some of the imidazoline derivatives had the ability to inhibit Pseudomonas and Escherichia coli. This difference in effect and inhibition potency of these substances is due to the presence of chlorine and phenyl compounds (15) . Beside the lack of effects of the 3a-b derivatives, experiments proved the power of methylnitroimidazole to inhibit the growth of the Enterobacteriaceae family such as Proteus vulgaris and Proteus mirabilis, and this compound could release free radicals that harm bacteria and kill them; this ability was not observed for the 3a-b derivatives (16) .
Compound 6 of thiazole could only inhibit S. dysenteriae, P. mirabilis, and L. monocytogenes among all the tested bacteria, and its inhibitory effect was much more on S. dysenteriae rather than P. mirabilis and L. monocytogenes. In the recent studies, inhibition of the bacterial DNA or enzymes has been proposed to be the influential mechanism for the inhibitory action of the thiazole derivatives. Inhibition of the bacterial enzyme ecKASIII (or FabH) (that is essential for the synthesis of fatty acids in Gram negative and gram positive bacteria) and the enzyme DNA-gyrase (that is needed to replicate the bacterial DNA) have been studied in some research works (17, 18) . Noting that the quinolone-family antibiotics and the thiazole derivatives could inhibit the subunits A and B in DNA-gyrase, respectively, is promising for the inhibition of the quinolone-resistant bacteria by the thiazole derivatives (18 proved the in-vitro potency of the thiazole derivatives to inhibit Salmonella typhi, Escherichia coli, Klebsiella pneumoniae, Vibrio cholera, and Staphylococcus aureus by measuring the values for the growth inhibition zone diameter and MIC (24) . Juspin et al. have carried out an experiment, in which the growth inhibition zone diameter and MIC values were measured, and the in-vitro power of the thiazole derivatives to inhibit the activities of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus was confirmed (25) .
CONCLUSION
With respect to the inhibitory effect of the thiazole derivatives and their synergistic effect with other antibiotics, it is suggested to assess their therapeutic and toxic effect in laboratory animals, and is recommended to do more researches in order to better recognize these compounds and their possible functionality.
